Quoin Pharmaceuticals Q3 net loss widens 23% to $4.87 million

Bitget2026/11/05 13:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Quoin Pharmaceuticals’ third-quarter 2026 net loss widened 23% year over year to $4.87 million.
Cash, cash equivalents and marketable securities totaled approximately $33.2 million at September 30, 2026.
Interim results from the QRX003 Phase 2/3 Netherton Syndrome study achieved statistical significance for the primary and key secondary endpoints.
Management expects to complete recruitment by year-end 2026 and report topline results in the second quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050830PRIMZONEFULLFEED9870862) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Quoin Pharmaceuticals Q3 net loss widens 23% to $4.87 million

You may also like

Crypto prices